-Bloomberg
SVB Leerink Initiates Coverage On CRISPR Therapeutics with Outperform Rating, Announces Price Target of $126
SVB Leerink analyst Rick Bienkowski initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform rating and announces Price Target of $126.